BioNTech SE
BNTXHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframePart of the healthcare sector, BioNTech SE (BNTX) is listed under Biotechnology. The company carries a $24.26B market cap, placing it firmly in the large-cap category. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Market Cap
$24.26B
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
-18.40
EPS (TTM)
$-5.89
EPS (Fwd)
$-5.21
ROE
-6.7%
ROA
-4.2%
Cash
$13.71B
Total Debt
$302.8M
Free CF
-$428.1M
52W Change
-15.2%
Annual Financials
Cash vs Debt
BioNTech SE holds $13.71B in cash against $302.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$428.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -6.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $17.31B (2022) to $2.87B (2025), a 83% decline worth watching.
With cash comfortably exceeding debt, BNTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BNTX.